1064 related articles for article (PubMed ID: 29657129)
1. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.
Tsoi J; Robert L; Paraiso K; Galvan C; Sheu KM; Lay J; Wong DJL; Atefi M; Shirazi R; Wang X; Braas D; Grasso CS; Palaskas N; Ribas A; Graeber TG
Cancer Cell; 2018 May; 33(5):890-904.e5. PubMed ID: 29657129
[TBL] [Abstract][Full Text] [Related]
2. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
3. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
5. The role of ferroptosis in melanoma.
Talty R; Bosenberg M
Pigment Cell Melanoma Res; 2022 Jan; 35(1):18-25. PubMed ID: 34407291
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.
Madorsky Rowdo FP; Barón A; Gallagher SJ; Hersey P; Emran AA; Von Euw EM; Barrio MM; Mordoh J
Int J Oncol; 2020 Jun; 56(6):1429-1441. PubMed ID: 32236593
[TBL] [Abstract][Full Text] [Related]
7. Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
Delgado-Goñi T; Galobart TC; Wantuch S; Normantaite D; Leach MO; Whittaker SR; Beloueche-Babari M
Br J Cancer; 2020 Jan; 122(1):72-81. PubMed ID: 31819183
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.
Molnár E; Garay T; Donia M; Baranyi M; Rittler D; Berger W; Tímár J; Grusch M; Hegedűs B
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514305
[TBL] [Abstract][Full Text] [Related]
9. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
10. FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor.
Sun Q; Novak D; Hüser L; Poelchen J; Wu H; Granados K; Federico A; Liu K; Steinfass T; Vierthaler M; Umansky V; Utikal J
Int J Cancer; 2021 Aug; 149(3):657-674. PubMed ID: 33837564
[TBL] [Abstract][Full Text] [Related]
11. Targeting CDC7 sensitizes resistance melanoma cells to BRAF
Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY
Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenib‑resistant melanoma cell lines.
Takahashi T; Abe N; Kanoh H; Banno Y; Seishima M
Mol Med Rep; 2018 Dec; 18(6):5151-5158. PubMed ID: 30320355
[TBL] [Abstract][Full Text] [Related]
13. CAMKK2 Defines Ferroptosis Sensitivity of Melanoma Cells by Regulating AMPK‒NRF2 Pathway.
Wang S; Yi X; Wu Z; Guo S; Dai W; Wang H; Shi Q; Zeng K; Guo W; Li C
J Invest Dermatol; 2022 Jan; 142(1):189-200.e8. PubMed ID: 34242660
[TBL] [Abstract][Full Text] [Related]
14. [Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
Ryabaya OO; Malysheva AA; Khochenkova YA; Solomko ES; Khochenkov DA
Mol Biol (Mosk); 2018; 52(3):466-473. PubMed ID: 29989578
[TBL] [Abstract][Full Text] [Related]
15. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
Fallahi-Sichani M; Becker V; Izar B; Baker GJ; Lin JR; Boswell SA; Shah P; Rotem A; Garraway LA; Sorger PK
Mol Syst Biol; 2017 Jan; 13(1):905. PubMed ID: 28069687
[TBL] [Abstract][Full Text] [Related]
16. Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
Liu X; Li Z; Li M; Chai J; He S; Wu J; Xu J
Oncol Rep; 2020 Jul; 44(1):360-370. PubMed ID: 32319656
[TBL] [Abstract][Full Text] [Related]
17. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
18. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
19. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
20. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
Doudican NA; Orlow SJ
Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]